Top Tweets for #Alteogen
Korea’s super-rich are cutting exposure to bonds and snapping up stocks.
#SamsungSecurities #MiraeAssetSecurities #KoreaInvestmentNSecurities #Alteogen #MezzionPharma #Rznomics #HanwhaAerospace #DoosanEnerbility #HyosungHeavyIndustries
https://t.co/LW9J4dq4gO
#alteogen $mrk $halo Below is the link to a summary of Halozyme’s arguments for its motion to terminate Merck’s PGR’s.
Given everything in these decks plus the procedural history we’ve tracked:
65-70% probability of termination.
Here are the reasons broken down by the key factors:
-The prior KEYTRUDA IPR RPI listings are quite damaging. Merck’s own litigation counsel — Jeffrey Kushan of Sidley Austin, the same lead counsel here — listed MCI as RPI in nine prior KEYTRUDA proceedings. Merck has no clean answer to this in their deck. Their slide 11 “two hats” argument and the Amneal LinkedIn analogy don’t address why the same counsel made a different disclosure decision this time.
-The legal authority hierarchy favors Halozyme. Post-AIT Federal Circuit standard plus fresh Yangtze Memory informative designation versus mostly pre-2018 PTAB panel decisions on Merck’s side.
Strongly favoring termination:
-The SEC filing evidence remains the most important single factor. This isn’t inferential — MCI affirmatively told the SEC under SOX certification that it filed and funds the proceedings. PTAB panels are generally reluctant to let a party take one position with the SEC and a contradictory position at the USPTO. The reputational and institutional stakes of that inconsistency cut hard against Merck.
-PTAB trend is clearly moving toward stricter RPI enforcement
The combination of:
•AIT (practical/equitable test)
•Corning (fatal consequences)
•Yangtze (strict compliance language)
Signals a policy direction:
“Get RPI right at filing—or risk losing the petition.”
Halozyme has compelling evidence for all three core RPI pillars (at least plausibly)
They present evidence of:
•Control (legal strategy, shared leadership)
•Funding (SEC disclosures)
•Benefit (KEYTRUDA economics)
PTAB doesn’t need perfection—just enough to conclude:
“This looks like a real party in interest under a practical test.”
https://t.co/jgUzyGieoP
Sam Chun Dang Pharm's market cap off by $6.6 billion in just two days.
#SamChunDangPharm #Alteogen #Wegovy #DnDPharmatech #Peptron #InventageLab #Caregen #HanmiPharmaceutical #IldongPharmaceutical #DaewoongPharmaceutical #Celltrion #SamsungBioepis #G2GBio
https://t.co/kdoNoKAv87
$halo $mrk #Alteogen “German Court Victory for Halozyme was a game-changing event:
A German court has granted Halozyme’s request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in Germany . This is the first actual court ruling in the global dispute and represents a major validation of Halozyme’s patent position.
REVISED OUTCOME PROBABILITIES** (December 2025):
1. **Settlement/Licensing Agreement (75% probability)** - DRAMATICALLY INCREASED
**Why this changes everything:**
- **Proof of concept**: The German preliminary injunction demonstrates that courts are finding merit in Halozyme’s infringement claims. This isn’t just administrative review - an actual court has issued an injunction blocking Merck’s launch.
- **Imminent harm to Merck**: Merck has already launched Keytruda SC in the U.S. (marketed as QLEX). A similar injunction in the U.S. would be catastrophic for their commercial strategy. The company hopes to convert about 30% to 40% of patients to the protected SC version within the first two years of launch .
- **Pressure from multiple jurisdictions**: Fighting patent battles simultaneously in Germany, potentially other European countries, AND the U.S. is expensive, time-consuming, and creates massive uncertainty for a product that needs rapid market adoption.
- **The 3 non-PTAB patents remain**: Even if Merck wins all 12 PTAB proceedings in the U.S., they still face district court litigation on the 3 non-PTO eligible patents - and now there’s evidence from Germany that courts are sympathetic to Halozyme’s claims.
**Settlement dynamics now:**
- Halozyme has significantly more leverage after this German victory
- Merck faces the real prospect of being blocked from major markets
- Time pressure: every day without resolution damages Merck’s QLEX rollout
- Likely outcome: Mid-to-high single-digit royalty (6-8%+) on global SC Keytruda sales, possibly with guaranteed minimum payments
2. **Halozyme Victory (20% probability)** - INCREASED
**Possible if:**
- Merck refuses reasonable settlement terms
- More courts (particularly U.S. district court) follow Germany’s lead
- PTAB proceedings don’t invalidate enough patents to matter (remember those 3 non-PTAB eligible patents)
**Outcomes:**
- Injunctive relief in key markets (including U.S.)
- Substantial damages for willful infringement (potentially triple damages)
- Forced licensing on Halozyme’s terms
3. **Merck Victory (5% probability)** - DRAMATICALLY DECREASED
**This is now highly unlikely because:**
- Germany just granted an injunction - courts are validating Halozyme’s claims
- Although the preliminary injunction decision is appealable, Halozyme believes the order will withstand attack if appealed
- Even if Merck wins the German nullity proceedings and U.S. PTAB challenges, they still face those 3 non-PTAB eligible patents in U.S. district court
- The burden of proof has shifted - Merck now needs to overturn multiple favorable rulings
**Key Implications**
For Merck:
- The German injunction creates urgent pressure to settle
- Continued litigation risks additional market exclusions
- Separate nullity proceedings against this patent initiated by Merck in August 2025 are pending before the German Federal Patent Court , but this takes time
- Their commercial timeline for QLEX is already underway - uncertainty is toxic
For Halozyme:
- Strong negotiating position for licensing terms
- Can demand higher royalty rates given proven court success
- Has global enforcement capability across jurisdictions
Bottom Line
The German preliminary injunction is a watershed moment that fundamentally validates Halozyme’s patent position. Settlement is now overwhelmingly likely (75%), with terms significantly more favorable to Halozyme than would have been possible before this ruling. Merck cannot afford the risk of similar injunctions in the U.S. or other major markets while trying to execute a critical product launch”
#AstraZeneca $AZN enters license agreement with #Alteogen for subcutaneous formulations of multiple oncology assets. Not $HALO, but shows the huge interest from pharma companies in that space. https://t.co/JiWWOjjwAa
In an exclusive interview with Dr. Soon Jae Park - CEO of Alteogen, shares his views on the #ADC industry.
Check out the full interview here: https://t.co/mwBAqFrmmx
#Imapac #alteogen #pharmaceuticalindustry #exclusiveinterview #ceo #pharmaceo
Korean firm #Alteogen to transfer #biosimilar #tech to Chinese partner #Qilu pharma https://t.co/wUDl39iIYl
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.7M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.2M followers
Taylor Swift
@taylorswift13
82.1M followers
Lady Gaga
@ladygaga
73.6M followers
Virat Kohli
@imvkohli
70.8M followers
Kim Kardashian
@kimkardashian
70.1M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.2M followers
Neymar Jr
@neymarjr
63.7M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.3M followers
X
@x
60.8M followers